CCDI: a new ligand that modulates mammalian type 1 ryanodine receptor (RyR1)

Br J Pharmacol. 2014 Sep;171(17):4097-111. doi: 10.1111/bph.12764. Epub 2014 Jul 2.

Abstract

Background and purpose: Ryanodine receptors (RyRs) are Ca(2+)-release channels on the sarco(endo)plasmic reticulum that modulate a wide array of physiological functions. Three RyR isoforms are present in cells: RyR1, RyR2 and RyR3. To date, there are no reports on ligands that modulate RyR in an isoform-selective manner. Such ligands are not only valuable research tools, but could serve as intermediates for development of therapeutics.

Experimental approach: Pyrrole-2-carboxylic acid and 1,3-dicyclohexylcarbodiimide were allowed to react in carbon tetrachloride for 24 h at low temperatures and pressures. The chemical structures of the two products isolated were elucidated using NMR spectrometry, mass spectrometry and elemental analyses. [(3) H]-ryanodine binding, lipid bilayer and time-lapsed confocal imaging were used to determine their effects on RyR isoforms.

Key results: The major product, 2-cyclohexyl-3-cyclohexylimino-2, 3, dihydro-pyrrolo[1,2-c]imidazol-1-one (CCDI) dose-dependently potentiated Ca(2+)-dependent binding of [(3)H]-ryanodine to RyR1, with no significant effects on [(3)H]-ryanodine binding to RyR2 or RyR3. CCDI also reversibly increased the open probability (P(o)) of RyR1 with minimal effects on RyR2 and RyR3. CCDI induced Ca(2+) transients in C2C12 skeletal myotubes, but not in rat ventricular myocytes. This effect was blocked by pretreating cells with ryanodine. The minor product 2-cyclohexyl-pyrrolo[1,2-c]imidazole-1,3-dione had no effect on either [(3)H]-ryanodine binding or P(o) of RyR1, RyR2 and RyR3.

Conclusions and implications: A new ligand that preferentially modulates RyR1 was identified. In addition to being an important research tool, the pharmacophore of this small molecule could serve as a template for the synthesis of other isoform-selective modulators of RyRs.

Keywords: 2-cyclohexyl-3-cyclohexylimino-2,3-dihydro-pyrrolo[1,2-c]imidazol-1-one (CCDI); isoforms-selective; ryanodine receptor; sarcoplasmic reticulum.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bridged Bicyclo Compounds, Heterocyclic / chemical synthesis
  • Bridged Bicyclo Compounds, Heterocyclic / chemistry
  • Bridged Bicyclo Compounds, Heterocyclic / pharmacology*
  • Calcium Channel Blockers / chemical synthesis
  • Calcium Channel Blockers / chemistry
  • Calcium Channel Blockers / pharmacology*
  • Cell Line
  • Dose-Response Relationship, Drug
  • HEK293 Cells
  • Humans
  • Imines / chemical synthesis
  • Imines / chemistry
  • Imines / pharmacology*
  • Ligands
  • Male
  • Mice
  • Molecular Structure
  • Rabbits
  • Rats
  • Ryanodine Receptor Calcium Release Channel / metabolism*
  • Structure-Activity Relationship

Substances

  • 2-cyclohexyl-3-cyclohexylimino-2,3-dihydropyrrolo(1,2-c)imidazol-1-one
  • Bridged Bicyclo Compounds, Heterocyclic
  • Calcium Channel Blockers
  • Imines
  • Ligands
  • Ryanodine Receptor Calcium Release Channel